Arcturus Therapeutics (NASDAQ:ARCT) Shares Pass Below Two Hundred Day Moving Average – Here’s What Happened

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) shares passed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $14.17 and traded as low as $6.07. Arcturus Therapeutics shares last traded at $6.25, with a volume of 749,736 shares changing hands.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on ARCT. Wall Street Zen raised Arcturus Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Guggenheim downgraded Arcturus Therapeutics from a “buy” rating to a “neutral” rating in a research note on Wednesday, October 22nd. Zacks Research cut shares of Arcturus Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, October 24th. Leerink Partners decreased their price target on shares of Arcturus Therapeutics from $63.00 to $54.00 and set an “outperform” rating on the stock in a report on Friday, August 22nd. Finally, Citigroup dropped their price objective on shares of Arcturus Therapeutics from $12.00 to $9.00 and set a “neutral” rating for the company in a research note on Thursday, November 13th. Seven analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Arcturus Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $36.00.

Arcturus Therapeutics Trading Down 3.7%

The business’s 50-day simple moving average is $13.24 and its two-hundred day simple moving average is $14.17. The firm has a market cap of $177.56 million, a price-to-earnings ratio of -2.54 and a beta of 2.10.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its quarterly earnings results on Monday, November 10th. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.09) by $0.60. Arcturus Therapeutics had a negative net margin of 68.35% and a negative return on equity of 28.68%. The firm had revenue of $17.15 million for the quarter, compared to the consensus estimate of $17.47 million. On average, analysts forecast that Arcturus Therapeutics Holdings Inc. will post -2.22 earnings per share for the current fiscal year.

Institutional Trading of Arcturus Therapeutics

A number of large investors have recently bought and sold shares of the business. US Bancorp DE raised its position in shares of Arcturus Therapeutics by 218.9% in the 1st quarter. US Bancorp DE now owns 3,393 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 2,329 shares in the last quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd acquired a new stake in Arcturus Therapeutics during the first quarter worth approximately $161,000. Vanguard Group Inc. increased its holdings in Arcturus Therapeutics by 3.8% in the first quarter. Vanguard Group Inc. now owns 1,748,928 shares of the biotechnology company’s stock worth $18,521,000 after purchasing an additional 64,367 shares in the last quarter. Deutsche Bank AG lifted its stake in Arcturus Therapeutics by 10.1% in the first quarter. Deutsche Bank AG now owns 27,280 shares of the biotechnology company’s stock valued at $289,000 after buying an additional 2,512 shares during the period. Finally, Mitsubishi UFJ Asset Management Co. Ltd. boosted its holdings in shares of Arcturus Therapeutics by 9.2% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 14,693 shares of the biotechnology company’s stock worth $156,000 after buying an additional 1,232 shares in the last quarter. 94.54% of the stock is currently owned by institutional investors and hedge funds.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.